{"originalText": "，患者因“宫颈癌”于2015-09-02在我院于全麻上行腹腔镜上盆腔淋巴结清扫+腹主动脉旁淋巴结取样+广泛子宫+两侧输卵管切除术+左侧卵巢切除+右侧卵巢悬吊术。，术后病理检查示：宫颈腺癌，符合中肾管癌，侵犯宫颈壁全层及宫颈管内口。右盆腔淋巴结12枚，其中一枚查见转移癌（31622.15)。，免疫组化：ER(-) PR(-) CR(-) CK(-) P16(-) NAPSINA(-)PAX-8个别腺体弱阳性，P53(-) CEA(+) WT-1(-)KI-67阳性率50%。术后一般情况可，2015-09-14给予紫杉醇240MG+顺铂110MG化疗，化疗过程顺利，副反应不重。2015-10-9予紫杉醇240MG+顺铂110MG方案化疗，予心电监护，水极化，化疗过程顺利，无明显化疗反应。2015-11-9 在我院放疗二科予紫杉醇240MG D1 +顺铂40MG D1-3方案化疗，盆腔适形放疗中，放化疗过程顺利，情况好转出院。于2015-12-25日、2016-1-17日给予紫杉醇240MG+顺铂110MG药物化疗2次。现患者无腹痛，无发热，无腰骶疼痛。为求第6次化疗，门诊以“宫颈癌术后化疗”收入院。患者一般情况可，睡眠饮食可，大小便无明显异常，体重无明显减轻。", "entities": [{"label_type": "疾病和诊断", "overlap": 0, "start_pos": 5, "end_pos": 8}, {"label_type": "手术", "overlap": 0, "start_pos": 28, "end_pos": 79}, {"label_type": "疾病和诊断", "overlap": 0, "start_pos": 89, "end_pos": 93}, {"label_type": "疾病和诊断", "overlap": 0, "start_pos": 96, "end_pos": 100}, {"label_type": "解剖部位", "overlap": 0, "start_pos": 103, "end_pos": 105}, {"label_type": "解剖部位", "overlap": 0, "start_pos": 109, "end_pos": 112}, {"end_pos": 121, "label_type": "解剖部位", "overlap": 0, "start_pos": 115}, {"end_pos": 261, "label_type": "药物", "overlap": 0, "start_pos": 258}, {"end_pos": 269, "label_type": "药物", "overlap": 0, "start_pos": 267}, {"end_pos": 303, "label_type": "药物", "overlap": 0, "start_pos": 300}, {"end_pos": 311, "label_type": "药物", "overlap": 0, "start_pos": 309}, {"end_pos": 367, "label_type": "药物", "overlap": 0, "start_pos": 364}, {"end_pos": 379, "label_type": "药物", "overlap": 0, "start_pos": 377}, {"end_pos": 395, "label_type": "解剖部位", "overlap": 0, "start_pos": 393}, {"end_pos": 444, "label_type": "药物", "overlap": 0, "start_pos": 441}, {"end_pos": 452, "label_type": "药物", "overlap": 0, "start_pos": 450}, {"end_pos": 469, "label_type": "解剖部位", "overlap": 0, "start_pos": 468}, {"label_type": "解剖部位", "overlap": 0, "start_pos": 476, "end_pos": 477}, {"label_type": "解剖部位", "overlap": 0, "start_pos": 477, "end_pos": 478}, {"label_type": "疾病和诊断", "overlap": 0, "start_pos": 493, "end_pos": 498}]}
